SIRT2 and neoplasm: In conclusion, our study [9], and others [50,51], suggest that SIRT2 is a tumor promoter in melanoma cells and this sirtuin is a promising target in antimelanoma therapy; these levels may influence the overall survival of melanoma patients [51].